- Report
- February 2024
- 80 Pages
Europe
From €4577EUR$4,750USD£3,858GBP
- Report
- August 2023
- 150 Pages
North America
From €4577EUR$4,750USD£3,858GBP
- Report
- August 2023
- 300 Pages
Middle East, Africa
From €4722EUR$4,900USD£3,980GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4722EUR$4,900USD£3,980GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4722EUR$4,900USD£3,980GBP
- Report
- August 2023
- 300 Pages
Europe
From €4722EUR$4,900USD£3,980GBP
- Report
- February 2021
- 500 Pages
United States
From €1966EUR$2,040USD£1,657GBP
€2313EUR$2,400USD£1,949GBP
- Report
- February 2024
- 70 Pages
Japan
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Italy
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
India
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Germany
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Italy
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Oman
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
France
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4577EUR$4,750USD£3,858GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4577EUR$4,750USD£3,858GBP
Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more